This announcement is a separate document:
海普瑞：安信证券股份有限公司关于深圳市海普瑞药业集团股份有限公司2023年半年度业绩下降的临时受托管理事务报告
Haipuri: Anxin Securities Co., Ltd.\'s temporary fiduciary management affairs report on the decline in the performance of Shenzhen Haipuri Pharmaceutical Group Co., Ltd. for the third half year of 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.